GSK Plc’s shingles vaccine was linked to a longer delay in dementia onset than a competing shot, a finding that suggests superior protective powers against one of the world’s most threatening conditions. People who received the Shingrix vaccine lived an average of 164 days longer without a dementia diagnosis than those who got Merck & Co.’s Zostavax, according to a study published Thursday in the Nature Medicine journal.